药房公司提议从2026年5月1日起为利泰莫维提供资金,以防止干细胞移植病人被感染,并辅之以2 710万美元的扩大移植能力投资。 Pharmac proposes funding letermovir from 1 May 2026 to prevent CMV in stem cell transplant patients, backed by a $27.1 million investment to expand transplant capacity.

Pharmac计划自2026年5月1日起资助letermovir，以预防干细胞移植患者中的巨细胞病毒感染，尤其是那些免疫严重抑制且无法使用其他抗病毒药物的患者。 Pharmac is proposing to fund letermovir starting 1 May 2026 to prevent cytomegalovirus infections in stem cell transplant patients, especially those with severe immunosuppression who can’t use other antivirals. 该药物旨在减少严重感染,缩短住院时间,帮助病人在离家较近的地方康复。 The drug aims to reduce serious infections, shorten hospital stays, and help patients recover closer to home. 目前只有奥克兰、惠灵顿和克赖斯特彻奇有移植设施,许多人需要长途旅行。 Transplants are currently only available in Auckland, Wellington, and Christchurch, requiring long-distance travel for many. 一项2 710万美元的投资支持扩大移植能力、劳动力和基础设施,有可能使异种移植增加27%至38%。 A $27.1 million investment supports expanding transplant capacity, workforce, and infrastructure, potentially increasing allogeneic transplants by 27% to 38%. 2026年3月5日至19日正在征求公众反馈。 Public feedback is being sought from 5 to 19 March 2026.